European evidence based consensus on the diagnosis and management of Crohn’s disease: current management
- S P L Travis1,
- E F Stange2,
- M Lémann3,
- T Öresland4,
- Y Chowers5,
- A Forbes6,
- G D’Haens7,
- G Kitis8,
- A Cortot9,
- C Prantera10,
- P Marteau11,
- J-F Colombel12,
- P Gionchetti13,
- Y Bouhnik14,
- E Tiret15,
- J Kroesen16,
- M Starlinger17,
- N J Mortensen18,
- for the European Crohn’s and Colitis Organisation (ECCO)
- 1John Radcliffe Hospital, Oxford, UK
- 2Chefarzt, Abteilung für Innere Medizin 1 Schwerpunkte Gastroenterologie, Hepatologie und Endokrinologie, Robert Bosch Krankenhaus, Stuttgart, Germany
- 3Service de Gastroentérologie, Hôpital Saint-Louis, Paris, France
- 4Colorectal Unit, Department of Surgery, Sahlgrenska Universiteitssjukhuset/Östra, Gothenburg, Sweden
- 5Chaim Sheba Medical Center, Tel Hashomer, Israel 52621
- 6University College Hospital, London, UK
- 7Imelda GI Clinical Research Centre, Imelda Hospital, Bonheiden, Belgium
- 8Imelda GI Clinical Research Centre, Imelda Hospital, Bonheiden, Belgium
- 9Department of Gastroenterology, University Hospital, Lille, France
- 10Azienda Ospedaliera S. Camillo-Forlanini, Unita Operativa di Gastroenterologia, Rome, Italy
- 11Hospital Européen Department of Gastroenterology, Paris, France
- 12Hospital Huriez, Department of HepatoGastroenterology, CH et U, Lille, France
- 13Universita di Bologna, Bologna, Italy
- 14Hospital Lariboisière, Department of Gastroenterology, Paris, France
- 15Inserm, Paris, France, and Universite Pierre et Marie Curie, Paris, France
- 16Chirurgische Klinik I (Allgemein-, Gefäβ- und Thoraxchirurgie), Universitätsklinikum Benjamin Franklin, Freie Universität Berlin, Berlin, Germany
- 17Institute of Pathology, University of Graz, Austria
- 18Department of Colorectal Surgery, John Radcliffe, Oxford, UK
- Correspondence to:
Dr S P L Travis
John Radcliffe Hospital, Oxford OX3 9DU, UK; simon.travis{at}orh.nhs.uk; Professor E F Stange, Department of Internal Medicine 1, Robert Bosch Krankenhaus, PO Box 501120, Auerbachstr 110, 70341 Stuttgart, Germany; Eduard.Stange{at}rbk.de
- Received 12 September 2005
- Accepted 21 December 2005
- Revised 18 December 2005
Abstract
This second section of the European Crohn’s and Colitis Organisation (ECCO) Consensus on the management of Crohn’s disease concerns treatment of active disease, maintenance of medically induced remission, and surgery. The first section on definitions and diagnosis includes the aims and methods of the consensus, as well as sections on diagnosis, pathology, and classification of Crohn’s disease. The third section on special situations in Crohn’s disease includes postoperative recurrence, fistulating disease, paediatrics, pregnancy, psychosomatics, extraintestinal manifestations, and alternative therapy for Crohn’s disease.
- 5-ASA, mesalazine
- AZA, azathioprine
- CD, Crohn’s disease
- CDAI, Crohn’s disease activity index
- CRP, C reactive protein
- CsA, cyclosporin
- ECCO, European Crohn’s and Colitis Organisation
- ESR, erythrocyte sedimentation rate
- IBD, inflammatory bowel disease
- IFX, infliximab
- MTX, methotrexate
- 6-MP, 6-mercaptopurine
- NNH, number needed to harm
- NNT, number needed to treat
- UC, ulcerative colitis
Footnotes
-
Competing interests: the authors have variously received unrestricted educational grants, consultancy fees and/or hospitality from all pharmaceutical companies in the field of inflammatory bowel disease, but no author was paid for this work nor did any company contribute to the consensus statements or text.









